JOP20220213A1 - ناهضة مستقبل الببتيد-1 الشبيه بالغلوكاغون (glp-1)، وتركيبة صيدلانية تشتمل عليه، وطريقة تحضيره - Google Patents

ناهضة مستقبل الببتيد-1 الشبيه بالغلوكاغون (glp-1)، وتركيبة صيدلانية تشتمل عليه، وطريقة تحضيره

Info

Publication number
JOP20220213A1
JOP20220213A1 JOP/2022/0213A JOP20220213A JOP20220213A1 JO P20220213 A1 JOP20220213 A1 JO P20220213A1 JO P20220213 A JOP20220213 A JO P20220213A JO P20220213 A1 JOP20220213 A1 JO P20220213A1
Authority
JO
Jordan
Prior art keywords
same
pharmaceutical composition
glp
receptor agonist
preparing
Prior art date
Application number
JOP/2022/0213A
Other languages
English (en)
Inventor
Jun Park
Min Mi Jo
Young Kwan Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Priority claimed from KR1020210034452A external-priority patent/KR102563111B1/ko
Publication of JOP20220213A1 publication Critical patent/JOP20220213A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمركب جديد مفيد كعامل للعلاج أو الوقاية من أمراض التمثيل الغذائي المختلفة مثل البدانة andquot;السمنةandquot; obesity أو مرض السُكري diabetes وفرط شحميات الدم hyperlipidemia، عن طريق نشاط ناهضة مستقبل الببتيد -1 الشبيه بالغلوكاغون (GLP-1) وتمثيل غذائي ممتاز للأدوية والحركية الدوائية (DMPK)، أو أيزومر منه أو ملح منه مقبول صيدلانيًا، وتركيبة صيدلانية تشتمل على المُركَّب، وطريقة لتحضير المُركَّب.
JOP/2022/0213A 2020-03-18 2021-03-17 ناهضة مستقبل الببتيد-1 الشبيه بالغلوكاغون (glp-1)، وتركيبة صيدلانية تشتمل عليه، وطريقة تحضيره JOP20220213A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200033477 2020-03-18
KR1020210034452A KR102563111B1 (ko) 2020-03-18 2021-03-17 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
PCT/KR2021/003287 WO2021187886A1 (ko) 2020-03-18 2021-03-17 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법

Publications (1)

Publication Number Publication Date
JOP20220213A1 true JOP20220213A1 (ar) 2023-01-30

Family

ID=77771773

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0213A JOP20220213A1 (ar) 2020-03-18 2021-03-17 ناهضة مستقبل الببتيد-1 الشبيه بالغلوكاغون (glp-1)، وتركيبة صيدلانية تشتمل عليه، وطريقة تحضيره

Country Status (14)

Country Link
US (1) US20230203021A1 (ar)
JP (1) JP2023520181A (ar)
AU (1) AU2021237185B2 (ar)
BR (1) BR112022018646A2 (ar)
CA (1) CA3171173A1 (ar)
CL (1) CL2022002466A1 (ar)
CO (1) CO2022014271A2 (ar)
IL (1) IL296336A (ar)
JO (1) JOP20220213A1 (ar)
MX (1) MX2022011349A (ar)
PE (1) PE20230175A1 (ar)
TW (1) TWI825398B (ar)
WO (1) WO2021187886A1 (ar)
ZA (1) ZA202210199B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
EP4192831A4 (en) 2020-08-06 2024-05-15 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4317145A1 (en) 2021-03-24 2024-02-07 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
JP2024514259A (ja) * 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法
KR20230173708A (ko) 2021-04-21 2023-12-27 길리애드 사이언시즈, 인코포레이티드 카르복시-벤즈이미다졸 glp-1r 조절 화합물
CA3218345A1 (en) 2021-05-20 2022-11-24 Francisco Javier Agejas Chicharro Macrocyclic glucagon-like peptide 1 receptor agonists
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2023222084A1 (zh) * 2022-05-20 2023-11-23 成都地奥九泓制药厂 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
WO2024063140A1 (ja) * 2022-09-22 2024-03-28 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を有する単環化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201291236A1 (ru) * 2010-05-13 2013-11-29 Эмджен Инк. Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
US8778923B2 (en) * 2011-12-12 2014-07-15 Receptos, Inc. GLP-1 receptor modulators
EP3555064B9 (en) * 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
AU2018243691B2 (en) * 2017-03-27 2022-05-12 Cardurion Pharmaceuticals, Llc Heterocyclic compound
US11858916B2 (en) * 2018-06-15 2024-01-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CN113853371B (zh) * 2019-04-12 2024-05-03 上海齐鲁锐格医药研发有限公司 Glp-1r激动剂及其用途
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CR20220178A (es) * 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
EP4069686A4 (en) * 2019-12-02 2022-11-09 Hyundai Pharm Co., Ltd. GLP-1 RECEPTOR AGONIST
EP4103563A4 (en) * 2020-02-13 2024-03-06 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS

Also Published As

Publication number Publication date
ZA202210199B (en) 2023-06-28
US20230203021A1 (en) 2023-06-29
WO2021187886A1 (ko) 2021-09-23
PE20230175A1 (es) 2023-02-01
TWI825398B (zh) 2023-12-11
IL296336A (en) 2022-11-01
MX2022011349A (es) 2022-11-10
CO2022014271A2 (es) 2022-10-21
TW202200559A (zh) 2022-01-01
CA3171173A1 (en) 2021-09-23
JP2023520181A (ja) 2023-05-16
AU2021237185A1 (en) 2022-10-06
BR112022018646A2 (pt) 2022-11-08
AU2021237185B2 (en) 2023-11-30
CL2022002466A1 (es) 2023-03-03

Similar Documents

Publication Publication Date Title
MX2022011349A (es) Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
MX2021006908A (es) Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
MX2022008066A (es) Compuestos triciclicos sustituidos.
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
SG11201901565VA (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
MX2020012967A (es) Combinacion farmaceutica que contiene activador de glucosacinasa y activador del receptor ppar, composicion, preparacion del compuesto, metodo de preparacion para el mismo y usos del mismo.
NZ721645A (en) Compounds for use as gpr120 agonists
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX2009009445A (es) Derivados novedosos de benzamida y proceso para la preparacion de los mismos.
EP2077846A4 (en) BENZOXAZEPINE COMPOUNDS, PREPARATION THEREOF AND USE THEREOF
MY147756A (en) Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
CR20210600A (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2023000943A (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
MX2019010108A (es) Derivados de azetidina.
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MY162554A (en) Novel benzamide derivatives